Haemonetics
286 hedge funds and large institutions have $5.89B invested in Haemonetics in 2020 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 73 increasing their positions, 117 reducing their positions, and 32 closing their positions.
66% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 32
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
37% more capital invested
Capital invested by funds: $4.29B → $5.89B (+$1.6B)
7% more funds holding
Funds holding: 268 → 286 (+18)
0.37% more ownership
Funds ownership: 97.52% → 97.89% (+0.37%)
14% less call options, than puts
Call options by funds: $17.6M | Put options by funds: $20.6M
38% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 117
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCOV
London Company of Virginia
Richmond,
Virginia
|
+$101M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$87.4M |
| 3 |
HM
HealthCor Management
New York
|
+$61M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$37.3M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
+$32.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$149M |
| 2 |
Renaissance Technologies
New York
|
-$38.5M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$33.3M |
| 4 |
Two Sigma Investments
New York
|
-$25.8M |
| 5 |
Two Sigma Advisers
New York
|
-$25.5M |
HAE Hedge Fund Activity: Q4 2020 in Review
286 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2020, worth a combined $5.89B — up 37% from $4.29B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new HAE positions and 32 closed out — a net gain of 21 holders — while 73 added to existing stakes and 117 trimmed.
The largest buyer was London Company of Virginia, opening a new position worth an estimated $101M. The largest seller was Point72 Asset Management, cutting an estimated $149M.
- 286 institutional investors held Haemonetics (HAE) as of Q4 2020, up from 268 in Q3 2020.
- Funds reported $5.89B of Haemonetics stock for Q4 2020, up 37% quarter-over-quarter.
- 53 funds opened new Haemonetics positions in Q4 2020 and 32 closed out, a net change of +21 holders.
- The largest Haemonetics buyer in Q4 2020 was London Company of Virginia, an estimated $101M added.
- The largest Haemonetics seller in Q4 2020 was Point72 Asset Management, an estimated $149M sold.
Based on aggregated 13F filings for Q4 2020.